Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A

Songmao Zhenga Biologics Development Sciences, Janssen Biotherapeutics, Janssen R&D, Spring House, PA, USA

Fang Shenb Immunology Discovery, Clinical Pharmacology and Pharmacometrics, Janssen R&D, Spring House, PA, USA

Brian Jonesb Immunology Discovery, Clinical Pharmacology and Pharmacometrics, Janssen R&D, Spring House, PA, USA

Damien Finka Biologics Development Sciences, Janssen Biotherapeutics, Janssen R&D, Spring House, PA, USA

Brian Geista Biologics Development Sciences, Janssen Biotherapeutics, Janssen R&D, Spring House, PA, USA

Ivo Nnanec Clinical Pharmacology and Pharmacometrics, Janssen R&D, Spring House, PA, USA

Zhao Zhoub Immunology Discovery, Clinical Pharmacology and Pharmacometrics, Janssen R&D, Spring House, PA, USA

Jeff Hallb Immunology Discovery, Clinical Pharmacology and Pharmacometrics, Janssen R&D, Spring House, PA, USA

Ravi Malaviyab Immunology Discovery, Clinical Pharmacology and Pharmacometrics, Janssen R&D, Spring House, PA, USA

Tatiana Ortb Immunology Discovery, Clinical Pharmacology and Pharmacometrics, Janssen R&D, Spring House, PA, USA

Weirong Wangc Clinical Pharmacology and Pharmacometrics, Janssen R&D, Spring House, PA, USACorrespondence[email protected]

Your download is now in progress and you may close this window